Technion Patents Heparanase-Neutralizing A54 mAb

Tue, 21 Apr 2026 14:20:15 +0000
Intellectual Property

The USPTO granted patent US12606637B2 to Technion Research & Development Foundation Limited on April 21, 2026. The patent covers heparanase-neutralizing monoclonal antibody A54 (IgG-1 mAb), its epitope HBD-II, pharmaceutical compositions, and uses for treating cancer, inflammation, viral infections, diabetes, and related complications. The patent also discloses combinatorial cancer therapies combining the A54 mAb with chemotherapy or radiation.